You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 6,699,493


✉ Email this page to a colleague

« Back to Dashboard


Title: Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
Abstract:Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
Inventor(s): Wong; Vernon G. (Menlo Park, CA)
Assignee: Oculex Pharmaceuticals, Inc. (Sunnyvale, CA)
Filing Date:Nov 28, 2001
Application Number:09/997,094
Claims:1. A method for preventing transplant rejection in an eye of an individual, comprising: a) performing an ocular transplant procedure on an eye of an individual; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.

2. The method of claim 1, wherein the ocular transplant procedure is selected from the group consisting of retinal pigment epithelium (RPE) transplant and cornea transplant.

3. The method of claim 2, wherein the ocular transplant procedure is an RPE transplant.

4. The method of claim 2, wherein the ocular transplant procedure is a cornea transplant.

5. The method of claim 1, wherein the bioerodible drug delivery system is placed in the anterior chamber of the eye.

6. The method of claim 1, wherein the bioerodible drug delivery system is placed in the vitreous cavity of the eye.

7. The method of claim 1, wherein the immunosuppressive agent is selected from the group consisting of dexamethasone, cyclosporin A, azathioprine, brequinar, gusperimus, 6-mercaptopurine, mizoribine, rapamycin, tacrolimus (FK-506), denopterin, edatrexate, methotrexate, piritrexim, pteropterin, raltitrexed, trimetrexate, cladribine, fludarabine, 6-mercaptopurine, thiamiprine, thiaguanine, ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, doxifluridine, emitefur, enocitabine, floxuridine, fluorouracil, gemcitabine, egafur, fluocinolone, triaminolone, anecortave acetate, fluorometholone, medrysone, and prednislone.

8. The method of claim 7, wherein the immunosuppressive agent is dexamethasone.

9. The method of claim 8, wherein the bioerodible drug delivery system comprises about 50% by weight of dexamethasone, about 15% by weight of hydroxypropyl methylcellulose and about 35% by weight of polylactic polyglycolic acid.

10. The method of claim 8, wherein the bioerodible drug delivery system comprises about 60% by weight of dexamethasone and about 40% by weight of polylactic polyglycolic acid.

11. The method of claim 8, wherein the bioerodible drug delivery system comprises about 50% by weight of dexamethasone and about 50% by weight of polylactic polyglycolic acid.

12. The method of claim 7, wherein the immunosuppressive agent is cyclosporin A.

13. The method of claim 1, wherein the bioerodible polymer is a polyester.

14. The method of claim 1, wherein the bioerodible polymer is a polylactic acid polyglycolic acid copolymer.

15. The method of claim 14, wherein the bioerodible drug delivery system further comprises hydroxy propyl methyl cellulose.

16. The method of claim 1, wherein the individual is a human.

17. A method for preventing transplant rejection in the eye of an individual, comprising: a) performing an ocular transplant procedure on an eye of an individual; and b) implanting a solid body into the eye, wherein the body comprises particles of an immunosuppressive agent entrapped within a bioerodible polymer, and whereby the agent is released from the body by erosion of the polymer.

18. A kit for preventing transplant rejection in an eye, comprising: a) a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer, wherein the drug delivery system is designed to be implanted in an eye of an individual who has undergone or is undergoing an ocular transplant procedure; and b) instructions for use.

19. The kit of claim 18, wherein the immunosuppressive agent is dexamethasone.

20. A method comprising a) performing a retinal pigment epithelium transplant or a cornea transplant on an eye of an individual; and b) placing in the eye a bioerodible drug delivery system comprising dexamethasone or cyclosporin A and a bioerodible polymer.

21. The method of claim 20, wherein the bioerodible drug delivery system is placed in an anterior chamber of the eye.

22. The method of claim 20, wherein the bioerodible drug delivery system is placed in a vitreous cavity of the eye.

23. The method of claim 20, wherein the bioerodible drug delivery system comprises about 50% by weight of dexamethasone or cyclosporin A, about 15% by weight of hydroxypropyl methylcellulose, and about 35% by weight of polylactic polyglycolic acid.

24. The method of claim 20, wherein the bioerodible drug delivery system comprises about 60% by weight of dexamethasone or cyclosporin A and about 40% by weight of polylactic polyglycolic acid.

25. The method of claim 20, wherein the bioerodible drug delivery system comprises about 50% by weight of dexamethasone or cyclosporin A and about 50% by weight of polylactic polyglycolic acid.

26. The method of claim 20, wherein the bioerodible polymer is a polyester.

27. The method of claim 20, wherein the bioerodible polymer is a polylactic acid polyglycolic acid copolymer.

28. The method of claim 20, wherein the bioerodible drug delivery system further comprises hydroxy propyl methyl cellulose.

29. The method of claim 20, wherein the individual is a human.

30. A method comprising placing in an eye of an individual a bioerodible drug delivery system; wherein the bioerodible drug delivery system includes an immunosuppressive agent and a bioerodible polymer; and wherein the eye of the individual has undergone or is undergoing an ocular transplant procedure.

31. The method of claim 30, wherein the ocular transplant procedure is selected from the group consisting of retinal pigment epithelium (RPE) transplant and cornea transplant.

32. The method of claim 31, wherein the ocular transplant procedure is an RPE transplant.

33. The method of claim 31, wherein the ocular transplant procedure is a cornea transplant.

34. The method of claim 30, wherein the bioerodible drug delivery system is placed in the anterior chamber of the eye.

35. The method of claim 30, wherein the bioerodible drug delivery system is placed in the vitreous cavity of the eye.

36. The method of claim 30, wherein the immunosuppressive agent is selected from the group consisting of dexamethasone, cyclosporin A, azathioprine, brequinar, gusperimus, 6-mercaptopurine, mizoribine, rapamycin, tacrolimus (FK-506), denopterin, edatrexate, methotrexate, piritrexim, pteropterin, raltitrexed, trimetrexate, cladribine, fludarabine, 6-mercaptopurine, thiamiprine, thiaguanine, ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, doxifluridine, emitefur, enocitabine, floxuridine, fluorouracil, gemcitabine, egafur, fluocinolone, triaminolone, anecortave acetate, fluorometholone, medrysone, and prednislone.

37. The method of claim 36, wherein the immunosuppressive agent is dexamethasone.

38. The method of claim 30, wherein the bioerodible drug delivery system comprises about 50% by weight of dexamethasone, about 15% by weight of hydroxypropyl methylcellulose and about 35% by weight of polylactic polyglycolic acid.

39. The method of claim 30, wherein the bioerodible drug delivery system comprises about 60% by weight of dexamethasone and about 40% by weight of polylactic polyglycolic acid.

40. The method of claim 30, wherein the bioerodible drug delivery system comprises about 50% by weight of dexamethasone and about 50% by weight of polylactic polyglycolic acid.

41. The method of claim 36, wherein the immunosuppressive agent is cyclosporin A.

42. The method of claim 30, wherein the bioerodible polymer is a polyester.

43. The method of claim 30, wherein the bioerodible polymer is a polylactic acid polyglycolic acid copolymer.

44. The method of claim 30, wherein the bioerodible drug delivery system further comprises hydroxy propyl methyl cellulose.

45. The method of claim 30, wherein the individual is a human.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.